We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| CSL Limited | ASX:CSL | Australian Stock Exchange | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.80 | -0.65% | 276.37 | 276.00 | 276.90 | 277.41 | 275.14 | 276.16 | 1,560,327 | 07:50:00 |
From Dec 2019 to Dec 2024
By Robb M. Stewart
MELBOURNE, Australia--CSL Ltd.'s (CSL.AU) chief financial officer is set to take the reins of the specialty biopharmaceutical company's new influenza-vaccine business, which it aims to launch at the start of next year.
Gordon Naylor, who has had executive-management responsibility for the company's existing vaccines and pharmaceutical business since 2012, will remain in his current role through a transition period with his successor, CSL said Thursday. The company plans to begin an international search for a new CFO shortly.
CSL's proposed new global influenza-vaccine unit will combine its existing operation, bioCSL, and the influenza-vaccine business bought from Novartis AG (NVS) last October for US$275 million. The new vaccine-manufacturing business will have plants in the U.S., U.K., Germany and Australia.
Write to Robb M. Stewart at robb.stewart@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year CSL Chart |
1 Month CSL Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
